Nektar Therapeutics

Nektar Therapeutics (Nektar) is an American biopharmaceutical company. The company was founded in 1990 and is based in San Francisco, California.[2] The company develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify chemical structure of substances.[3] It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc.[2] The company developed the world's first inhalable non-injectable insulin, Exubera, which was awarded as the bronze award by Wall Street Journal for its technological breakthrough.[4]

Nektar Therapeutics
FormerlyInhale Therapeutic Systems, Inc.
TypePublic company
IndustryBiopharmaceuticals
Founded1990 (1990)
HeadquartersSan Francisco, California, U.S.
Products
RevenueUS$1.13 billion (2018)[1]
Number of employees
718 (2020)
Websitenektar.com

Background

The company is engaged in developing a proprietary pipeline of drug candidates for several therapeutic areas including oncology, pain, anti-infectives, anti-viral and immunology.[2] The company's research and development involve in small molecule and biologic drug candidates. Its drug candidate base consists of naloxegol (Movantik), a Phase III oral opioid antagonist, etirinotecan pegol, a topoisomerase inhibitor under Phase III clinical study as of 2012, NKTR 061, NKTR-181, NKTR-214, etc.[5]

In 2013, the company was assigned a patent which was developed by the company and other four co-inventors.[6] The products of the company is served as a supplement to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability and other areas of drugs for the patients worldwide.[7] As of March 2014, the company had a market capitalization of $1.7 billion with an enterprise value of $1.67 billion.[1] As of July 15, 2019, the company had a market cap of $5.88 Billion.

Pipeline

Etirinotecan pegol was in the phase III BEACON trial as well as in the I-SPY2 adaptive clinical trial for breast cancer in 2016.[8] The European Medicines Agency refused a marketing authorisation in 2017.[9]

Bempegaldesleukin (NKTR-214) is a CD122-biased immune-stimulatory cytokine,[10] Phase I results were announced in November 2016.[11] It is now in a phase 2 trial in combination with nivolumab for various advanced cancers.[12]

References
  1. "NKTR Key Statistics | Nektar Therapeutics Inc Stock - Yahoo! Finance". Finance.yahoo.com. Retrieved 2014-03-16.
  2. "BDR: Summary for Nektar Therapeutics, Inc.- Yahoo! Finance". Finance.yahoo.com. Retrieved 2014-03-17.
  3. "Nextar Therapeutics Inc. brief introduction NASDAQ". Nasdaq.com. Retrieved 2014-03-16.
  4. Totty, Michael (2006-09-11). "The Winners Are..." Wall Street Journal. ISSN 0099-9660. Retrieved 2020-01-22.
  5. "NKTR reuter.com". Reuters.com. Archived from the original on 2014-03-16. Retrieved 2014-03-16.
  6. "Nektar Therapeutics : U.S. Patents Awarded to Inventors in Alabama (Feb. 8)". 4-traders.com. 2014-02-08. Retrieved 2014-03-16.
  7. "Nextar Marketwatch Quote Summary". Marketwatch.com. Retrieved 2014-03-16.
  8. Novel Agents are Targeting Drivers of TNBC - Several drug candidates in I-SPY2 have 'graduated' to later-phase studies. 2016
  9. "Onzeald". European Medicines Agency. 2017-11-10.
  10. "Nektar and MD Anderson Cancer Center Announce Phase 1/2 Clinical Research Collaboration for NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine". Nektar Therapeutics. June 2, 2015. Archived from the original on 19 December 2017. Retrieved 25 June 2015.
  11. Martins, Ines. "Immunotherapy, NKTR-214, Shows Activity Against Solid Tumors in Study". Retrieved 2020-11-12.
  12. "NKTR-214/Nivolumab Combination Shows Promise in Early Study". OncLive. Retrieved 2020-11-12.
  • Official website
  • Business data for Nektar Therapeutics:
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.